Monday, September 21

Keynote Address
Robert H. Vonderheide, University of Pennsylvania, USA
Harnessing Myeloid Cells in the Treatment of Cancer

Ontogeny of Myeloid Cells in Cancer
Miriam Merad, Mount Sinai School of Medicine, USA
Talk Title to be Announced
Judith A. Varner, University of California, San Diego, USA
Mechanisms Governing Accumulation of Macrophages in Cancer
Dmitry I. Gabrilovich, AstraZeneca, USA
Monocyte-Like Precursors of Granulocytes in Cancer

Epigenetics, Metabolism and Metastasis of Myeloid Cells in Cancer
Gwendalyn J. Randolph, Washington University, USA
Serous Cavity Macrophages and Ovarian Cancer in the Peritoneum-Studies in Mice
Catherine Hedrick, La Jolla Institute for Immunology, USA
Myeloid Cells in Modulating Cancer Metastasis
Weiping Zou, University of Michigan, USA
Aerobic Glycolysis and Myeloid-Derived Suppressor Cells
Diana Hargreaves, The Salk Institute for Biological Studies, USA
Epigenetic Control of Myeloid Cells in Cancer
Florent Ginhoux, Singapore Immunology Network, Singapore
Macrophage and Dendritic Cell Biology: From Development to Functions

Poster Session

Tuesday, September 22

Immune Suppression and Metastasis Mediated by Myeloid Cells
Jeffrey W. Pollard, Queen's Medical Research Institute, UK
Re-tuning the Tumor Microenvironment to Promote Immunotherapy
Jo A. Van Ginderachter, VIB-Vrije Universiteit Brussel, Belgium
Transcriptional Profiling of Glioblastoma-Associated Myeloid Cells across Species and Disease Stage Reveals Macrophage Competition and Functional Specialization
Vincenzo Bronte, University of Verona, Italy
DAB2-Expressing TAMs Promote Cancer Cell Invasion
Antonio Sica, University of Eastern Piedmont, Italy
Metabolic Regulation of Myeloid Derived Suppressor Cells in Cancer
Michael C. Schmid, Liverpool University, UK
Myeloid Cells in Pancreatic Cancer Metastasis

Promotion of Tumor Progression by Myeloid Cells

Wednesday, September 23

Targeting Myeloid Cells in Cancer Therapy I
Lisa M. Coussens, Oregon Health & Science University, USA
Therapeutic Targeting of Macrophages: Lessons Learned from Mouse Models and Their Translation to the Clinic
Limin Shang, Light Chain Bioscience, Switzerland
CD47 Targeting in Cancer Therapy
Simon T. Barry, AstraZeneca, UK
Therapeutic Targeting of Macrophages and Neutrophils
Nagy A. Habib, Imperial College London and MiNA Therapeutics, UK
MTL - CEBPA - Next Generation Immunotherapy Targeting Myeloid Cell Differentiation

Targeting Myeloid Cells in Cancer Therapy II
Brenda C. O’Connell, Infinity Pharmaceuticals, Inc, USA
Targeting PI3K-gamma with IPI-549, a Tumor Macrophage-Repurposing Small Molecule, in Patients with Advanced Solid Tumors
Jennifer Guerriero, Dana-Farber Cancer Institute, USA
Differentiating Macrophages are Regulated by PARP Inhibitors and can be Harnessed to Overcome PARP-Inhibitor Resistance in BRCA-Associated Triple-Negative Breast Cancer
David A. Cheresh, University of California, San Diego, USA
Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression

Closing Remarks (Organizers)